Helix Biopharma Corp.
HBPCF
$0.59
$0.135129.70%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 92.60% | -10.40% | 732.95% | 24.05% | 5.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.09% | 26.62% | 139.55% | 34.20% | -27.14% |
| Operating Income | -36.09% | -26.62% | -139.55% | -34.20% | 27.14% |
| Income Before Tax | -44.83% | -5.97% | -138.73% | -36.70% | 24.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.83% | -5.97% | -138.73% | -36.70% | 24.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.83% | -5.97% | -138.73% | -36.70% | 24.01% |
| EBIT | -36.09% | -26.62% | -139.55% | -34.20% | 27.14% |
| EBITDA | -36.33% | -26.71% | -139.86% | -34.20% | 27.21% |
| EPS Basic | -21.38% | 7.83% | -82.92% | -28.34% | 28.05% |
| Normalized Basic EPS | -23.23% | 8.09% | -82.61% | -28.57% | 28.26% |
| EPS Diluted | -154.09% | 7.83% | -82.92% | -28.34% | 28.05% |
| Normalized Diluted EPS | -23.23% | 8.09% | -82.61% | -28.57% | 28.26% |
| Average Basic Shares Outstanding | 19.27% | 15.17% | 30.42% | 6.56% | 5.37% |
| Average Diluted Shares Outstanding | 19.27% | 15.17% | 30.42% | 6.56% | 5.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |